Tebentafusp Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for Tebentafusp comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Melanoma. Most recent publication: Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study., J Immunother Cancer, 2023.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, et al. · J Immunother Cancer · 2023
PubMed: PMID 37286303 · NCT02535078 · Melanoma

Publications by year

2023–2023: 1 publications.

2023

Publications by indication

Melanoma (1)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
J Immunother Cancer · 2023 · PMID 37286303 · NCT02535078

Publications by journal

J Immunother Cancer1 paper

All Tebentafusp publications (1)

2023 (1 paper)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, et al. · J Immunother Cancer · 2023 · Derived
PubMed: PMID 37286303 · NCT02535078 · Melanoma

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:15:15 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).